

Ezra E Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7120080/publications.pdf>

Version: 2024-02-01

128
papers

12,311
citations

44444

50
h-index

31191

106
g-index

133
all docs

133
docs citations

133
times ranked

15633
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 1 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 393, 156-167. | 6.3 | 1,153 |
| 2 | PI3K β is a molecular switch that controls immune suppression. <i>Nature</i> , 2016, 539, 437-442. | 13.7 | 884 |
| 3 | Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4708-4713. | 0.8 | 593 |
| 4 | Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2003, 21, 1980-1987. | 0.8 | 568 |
| 5 | Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 632-641. | 3.2 | 525 |
| 6 | Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2735-2743. | 0.8 | 458 |
| 7 | American Cancer Society Head and Neck Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 203-239. | 157.7 | 419 |
| 8 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184. | | 413 |
| 9 | Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 1864-1871. | 0.8 | 353 |
| 10 | Stereotactic body radiotherapy for multisite extracranial oligometastases. <i>Cancer</i> , 2012, 118, 2962-2970. | 2.0 | 295 |
| 11 | Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 450-462. | 5.1 | 287 |
| 12 | Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3305-3313. | 0.8 | 269 |
| 13 | Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. <i>Lancet Oncology</i> , The, 2009, 10, 247-257. | 5.1 | 263 |
| 14 | Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984. | 0.8 | 240 |
| 15 | The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2009, 69, 3021-3031. | 0.4 | 236 |
| 16 | Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2005, 11, 8418-8424. | 3.2 | 224 |
| 17 | The Expanding Role of Systemic Therapy in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1743-1752. | 0.8 | 199 |
| 18 | Current Treatment Options for Metastatic Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 35-46. | 1.3 | 197 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021, 156, 281-293. | 0.3 | 157 |
| 20 | Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 2659-2665. | 0.8 | 144 |
| 21 | Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. <i>Clinical Cancer Research</i> , 2012, 18, 2056-2065. | 3.2 | 141 |
| 22 | Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011. | 0.8 | 141 |
| 23 | Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2015, 51, 291-298. | 0.8 | 136 |
| 24 | An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4546-4552. | 0.8 | 135 |
| 25 | Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. <i>Nature Genetics</i> , 2014, 46, 939-943. | 9.4 | 126 |
| 26 | Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. <i>Clinical Cancer Research</i> , 2005, 11, 8105-8108. | 3.2 | 125 |
| 27 | B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 3345-3359. | 3.2 | 117 |
| 28 | Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 883-892. | 5.1 | 116 |
| 29 | The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification. <i>Clinical Cancer Research</i> , 2021, 27, 689-703. | 3.2 | 113 |
| 30 | Erlotinib and the Risk of Oral Cancer. <i>JAMA Oncology</i> , 2016, 2, 209. | 3.4 | 111 |
| 31 | A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 766-770. | 1.5 | 106 |
| 32 | Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. <i>Cancer</i> , 2014, 120, 2694-2703. | 2.0 | 106 |
| 33 | A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2012, 18, 2336-2343. | 3.2 | 104 |
| 34 | New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Cancer Research</i> , 2010, 16, 2489-2495. | 3.2 | 102 |
| 35 | A Feed-Forward Loop Involving Protein Kinase C δ and MicroRNAs Regulates Tumor Cell Cycle. <i>Cancer Research</i> , 2009, 69, 65-74. | 0.4 | 99 |
| 36 | Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. <i>Nature Communications</i> , 2019, 10, 5546. | 5.8 | 98 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2427-2437. | 0.8 | 88 |
| 38 | Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4211-4223. | 3.2 | 85 |
| 39 | Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3336-3343. | 0.8 | 75 |
| 40 | Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer. <i>PLoS Computational Biology</i> , 2012, 8, e1002350. | 1.5 | 75 |
| 41 | An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1227-1239. | 1.1 | 73 |
| 42 | Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 246-253. | 1.1 | 73 |
| 43 | A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human Cancers. <i>Cancer Research</i> , 2010, 70, 2158-2164. | 0.4 | 72 |
| 44 | Protein Kinase C η Mediates Epidermal Growth Factor-Induced Growth of Head and Neck Tumor Cells by Regulating Mitogen-Activated Protein Kinase. <i>Cancer Research</i> , 2006, 66, 6296-6303. | 0.4 | 70 |
| 45 | Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. <i>Annals of Oncology</i> , 2017, 28, 2526-2532. | 0.6 | 70 |
| 46 | Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. <i>Cancer</i> , 2011, 117, 4671-4678. | 2.0 | 68 |
| 47 | Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. <i>Modern Pathology</i> , 2021, 34, 532-541. | 2.9 | 63 |
| 48 | Planned Post-Chemoradiation Neck Dissection: Significance of Radiation Dose. <i>Laryngoscope</i> , 2006, 116, 33-36. | 1.1 | 61 |
| 49 | Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 358-365. | 1.1 | 61 |
| 50 | Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 4785-4793. | 3.2 | 61 |
| 51 | Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161. | 3.2 | 58 |
| 52 | Characteristics Associated With Swallowing Changes After Concurrent Chemotherapy and Radiotherapy in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2008, 134, 1060. | 1.5 | 53 |
| 53 | Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. <i>Head and Neck</i> , 2009, 31, 1013-1021. | 0.9 | 53 |
| 54 | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. <i>Nature Communications</i> , 2016, 7, 13019. | 5.8 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Epidermal growth factor receptor directed therapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 25-43. | 2.0 | 46 |
| 56 | A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1261-1270. | 1.1 | 44 |
| 57 | Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1393-1399. | 3.0 | 43 |
| 58 | Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. <i>Translational Research</i> , 2011, 157, 265-272. | 2.2 | 42 |
| 59 | Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2012, 48, 887-892. | 0.8 | 42 |
| 60 | Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. <i>Oral Oncology</i> , 2018, 80, 16-22. | 0.8 | 42 |
| 61 | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. , 2019, 7, 342. | | 40 |
| 62 | Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. <i>Clinical Cancer Research</i> , 2021, 27, 6075-6082. | 3.2 | 40 |
| 63 | Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. <i>Nature Communications</i> , 2021, 12, 2383. | 5.8 | 39 |
| 64 | Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 678-684. | 0.4 | 38 |
| 65 | Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. <i>Molecular Oncology</i> , 2013, 7, 359-368. | 2.1 | 37 |
| 66 | HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. <i>Cancer Research</i> , 2020, 80, 732-746. | 0.4 | 36 |
| 67 | Multidisciplinary Care of Laryngeal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 717-724. | 2.5 | 35 |
| 68 | Tipifarnib in recurrent, metastatic HRAS mutant salivary gland cancer. <i>Cancer</i> , 2020, 126, 3972-3981. | 2.0 | 34 |
| 69 | Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. <i>Journal of Geriatric Oncology</i> , 2013, 4, 327-333. | 0.5 | 33 |
| 70 | Race and competing mortality in advanced head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 40-44. | 0.8 | 27 |
| 71 | Chemoradiation for patients with large-volume laryngeal cancers. <i>Head and Neck</i> , 2012, 34, 1162-1167. | 0.9 | 26 |
| 72 | p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors. <i>PLoS ONE</i> , 2014, 9, e90171. | 1.1 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Rare occurrence of EGFRVIII deletion in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 53-58. | 0.8 | 26 |
| 74 | Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. <i>Journal of the National Cancer Institute</i> , 2021, 113, 171-181. | 3.0 | 25 |
| 75 | A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. <i>Quality of Life Research</i> , 2007, 16, 1615-1626. | 1.5 | 24 |
| 76 | Multidisciplinary Care of the Patient with Head and Neck Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 179-215. | 0.6 | 23 |
| 77 | Efficient Cisplatin Prodrug Delivery Visualized with Sub-100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles with a Living System. <i>Advanced Materials Interfaces</i> , 2014, 1, 1400182. | 1.9 | 22 |
| 78 | Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. <i>Targeted Oncology</i> , 2015, 10, 501-508. | 1.7 | 22 |
| 79 | Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 5420-5426. | 3.2 | 22 |
| 80 | The Rise of HPV-Positive Oropharyngeal Cancers in the United States. <i>Cancer Prevention Research</i> , 2015, 8, 9-11. | 0.7 | 21 |
| 81 | Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 157-167. | 1.9 | 21 |
| 82 | Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. <i>Journal of Cancer Education</i> , 2018, 33, 622-626. | 0.6 | 20 |
| 83 | Novel therapeutic targets in squamous cell carcinoma of the head and neck. <i>Seminars in Oncology</i> , 2004, 31, 755-768. | 0.8 | 19 |
| 84 | Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors. <i>Current Cancer Drug Targets</i> , 2007, 7, 666-673. | 0.8 | 19 |
| 85 | Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). <i>Oral Oncology</i> , 2015, 51, 399-408. | 0.8 | 19 |
| 86 | High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 3438-3444. | 0.8 | 18 |
| 87 | Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. <i>Frontiers in Oncology</i> , 2018, 8, 435. | 1.3 | 18 |
| 88 | Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. <i>Ecological Management and Restoration</i> , 2008, 21, 514-521. | 0.2 | 17 |
| 89 | Factors Associated With Long-term Speech and Swallowing Outcomes After Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2010, 136, 1226. | 1.5 | 17 |
| 90 | Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens. <i>Cancer Immunology Research</i> , 2019, 7, 40-49. | 1.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. <i>PLoS ONE</i> , 2016, 11, e0152995. | 1.1 | 17 |
| 92 | Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 33. | 1.7 | 17 |
| 93 | Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. <i>Oral Oncology</i> , 2013, 49, 1025-1031. | 0.8 | 16 |
| 94 | Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 442-447. | 1.0 | 16 |
| 95 | Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. <i>Translational Cancer Research</i> , 2020, 9, 203-209. | 0.4 | 15 |
| 96 | Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. <i>Biomaterials</i> , 2020, 248, 120032. | 5.7 | 14 |
| 97 | DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. <i>PLoS ONE</i> , 2014, 9, e102112. | 1.1 | 14 |
| 98 | Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. <i>Oral Oncology</i> , 2012, 48, 1025-1030. | 0.8 | 13 |
| 99 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 309-317. | 1.1 | 12 |
| 100 | Novel targeted therapies in head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 281-295. | 1.9 | 11 |
| 101 | A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. <i>Cancer Investigation</i> , 2007, 25, 435-444. | 0.6 | 10 |
| 102 | Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-small-Cell Lung Cancer, A Phase II Trial. <i>Clinical Lung Cancer</i> , 2012, 13, 123-128. | 1.1 | 10 |
| 103 | Selection of Head and Neck Cancer Patients for Intensive Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 157-166. | 0.4 | 10 |
| 104 | Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. <i>Cancer Letters</i> , 2015, 359, 269-274. | 3.2 | 9 |
| 105 | Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 738626. | 1.3 | 9 |
| 106 | Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, e17-e19. | 0.6 | 8 |
| 107 | Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 81-90. | 0.9 | 6 |
| 108 | Analysis of <i>CDK12</i> alterations in a pan-cancer database. <i>Cancer Medicine</i> , 2022, 11, 753-763. | 1.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , 2019, 17, 429. | 1.8 | 5 |
| 110 | Treatment of metastatic urothelial cancer in the post-MVAC era. <i>World Journal of Urology</i> , 2001, 19, 126-132. | 1.2 | 3 |
| 111 | Open Access in biomedical sciences: What the current turning point means more specifically to Oral Oncology contributors and readers. <i>Oral Oncology</i> , 2013, 49, 985-986. | 0.8 | 3 |
| 112 | Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. <i>Clinical Cancer Research</i> , 2015, 21, 5092-5099. | 3.2 | 3 |
| 113 | Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2022, 51, 5. | 0.9 | 3 |
| 114 | Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. <i>Cancer</i> , 2017, 123, 4310-4313. | 2.0 | 1 |
| 115 | Did Everolimus Break the Rules?. <i>Clinical Cancer Research</i> , 2021, 27, 3807-3808. | 3.2 | 1 |
| 116 | Locally advanced non-small cell lung cancer. <i>Current Treatment Options in Oncology</i> , 2001, 2, 27-42. | 1.3 | 0 |
| 117 | A Disturbance in the Force—Mitochondrial Mutations in Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2007, 13, 4317-4319. | 3.2 | 0 |
| 118 | Personalizing cancer care: updates on head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1219-1222. | 1.1 | 0 |
| 119 | The Next Phase of Chemoprevention Research. <i>Cancer Prevention Research</i> , 2011, 4, 293-295. | 0.7 | 0 |
| 120 | Magnetomicelles: Efficient Cisplatin Prodrug Delivery Visualized with Sub-100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles With a Living System (<i>Adv. Mater. Interfaces</i>) Tj ETQq0 0 0rgBT /Overlock 10 | | |
| 121 | The ACR appropriateness criteria® for thyroid carcinoma: Searching for consensus in a rapidly evolving area. <i>Oral Oncology</i> , 2014, 50, 575-576. | 0.8 | 0 |
| 122 | Reply to S. Chakraborty et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 968-968. | 0.8 | 0 |
| 123 | Considering the survivorship care needs of head and neck cancer survivors. <i>Oral Oncology</i> , 2016, 57, 61-62. | 0.8 | 0 |
| 124 | Postoperative Management of High-Risk Resectable Head and Neck Cancer. , 2016, , 607-615. | | 0 |
| 125 | Characterizing an Ultra-High-Risk Subset of Patients With Hypopharynx and Larynx Cancer. <i>JAMA Oncology</i> , 2018, 4, 989. | 3.4 | 0 |
| 126 | p16 status and choice of chemotherapy in the KEYNOTE-040 study — Authors' reply. <i>Lancet</i> , The, 2019, 394, 1323. | 6.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Targeted Therapies in Head and Neck Cancer. , 2005, , 239-261. | | 0 |
| 128 | Inevitable Progress-Relying on the Immune System, Not Chance. Clinical Cancer Research, 2021, , clincanres.3739.2021. | 3.2 | 0 |